0
Inquiry Basket

There is no product in the shopping cart, buy it!

Anti-Sialic Acid Antibody Development Service

Overview

Sialic acids are terminal glycans often overexpressed on tumor cell surfaces, driving immune evasion through interactions with inhibitory Siglecs. Research demonstrates that hypersialylation is a hallmark of tumor progression and immune suppression, while antibodies targeting sialylated epitopes or blocking Siglec–sialic acid interactions can restore immune surveillance. With engineering innovations and enzyme-conjugated formats, antibody development against sialic acids now represents a promising route for cancer therapy and diagnostics. Anti-sialic acid antibody development service at Creative Biolabs helps you generate highly specific antibodies, restore anti-tumor immunity, and streamline development through advanced glycan-array screening, antibody engineering, and validated functional assays.

We combine glycan-array–guided discovery, Fc and framework engineering, and innovative antibody formats to create high-performance anti-sialic acid antibodies. Our strategies include:

  • Profiling tumor-specific sialylation patterns to identify actionable epitopes
  • Humanization and Fc optimization to reduce immunogenicity and enhance effector functions
  • Development of nanobodies and fragments for deeper tumor penetration
  • Integration of enzyme-armed antibodies, ADCs, and bispecific constructs for expanded functionality
  • Overcoming antigen heterogeneity and shedding through epitope mapping and structural refinement
  • Validation with functional assays such as Siglec-blocking, ADCC, and in vivo immune reactivation models

Accelerate Innovation with Creative Biolabs – Start Your Consultation Today

What We Can Offer

Epitope-Specific Discovery

Identification of antibodies against distinct sialylated motifs using glycan arrays and high-throughput screens.

Advanced Antibody Engineering

Humanization, affinity maturation, and Fc tuning to enhance therapeutic and diagnostic performance.

Custom Antibody Formats

Generation of IgGs, bispecifics, nanobodies, and antibody–enzyme conjugates tailored to project needs.

Functional Validation

In vitrocell assays and in vivo tumor models to confirm immune activation and target selectivity.

Analytical Services

Comprehensive sialylation quantification and glycan-specificity profiling for high-confidence candidate selection.

Deliverables

Well-characterized antibodies with binding, specificity, and functional data, plus tailored recommendations for the next stage of development.

Workflow

01Target Assessment

Evaluate tumor-associated sialylation patterns, supported by glycomics and expression data.

02Antigen Design

Develop synthetic sialylated antigens or conjugates for precise immunization and screening.

03Antibody Generation

Use hybridoma, phage display, or yeast display to identify panels of sialic acid–specific binders.

04Engineering & Optimization

Apply humanization, Fc engineering, and fragment design to improve efficacy and safety.

05Specificity & Functional Testing

Validate candidates with glycan arrays, Siglec-blocking assays, and immune activation studies.

06Preclinical Evaluation

Confirm activity in tumor models, assessing immune infiltration, ADCC, and cytokine responses.

Required Starting Materials

  • Structural or synthetic information on target sialylated glycans or conjugates
  • Supporting tumor expression data (glycomics, tissue staining, or cell line validation)
  • Intended application context

Highlights


Deep Glycan Expertise
Extensive experience in developing antibodies against complex glycans and glycoepitopes.

Innovative Modalities
Capability to design bispecifics, nanobodies, and antibody–enzyme conjugates for unique applications.

Advanced Analytics
Access to glycan arrays, glycomics, and functional immune assays ensures precise validation.

Discover the Creative Biolabs Advantage – Request Your Quote Now

Publication

O-glycan chain biosynthesis begins when peptidyl-N-acetylgalactosaminyltransferases (GalNAc-T) add an N-acetylgalactosamine residue to serine or threonine on a polypeptide, producing the Tn antigen. This structure can be elaborated in several ways: ST6GalNAc-I converts it into the sialyl-Tn (STn) antigen by adding Neu5Acα2–6GalNAc, T-synthase generates the T antigen (core-1), and C3GnT forms core-3 structures. Among these, Tn and STn are frequently overexpressed in tumors and serve as tumor-associated glycoepitopes. Monoclonal antibodies specifically designed to recognize these altered glycans, such as those targeting STn, provide valuable tools for cancer research and therapeutic development by enabling precise detection and potential immune-mediated elimination of malignant cells. Glycan microarray analysis of the anti-STn L2A5 monoclonal antibody further confirmed its selective binding to STn and short glycans carrying α2–6-linked sialic acid, demonstrating both its specificity and utility for mapping tumor-associated glycan signatures.

Fig.1 Analysis of anti-STn L2A5 mAb binding specificity using a glycan microarray. (OA Literature) Fig.1 Glycan array profiling of the anti-STn monoclonal antibody L2A5.1

Customer Reviews

Enhanced Specificity
Using Creative Biolabs' anti-sialic acid antibody development service improved our ability to distinguish tumor-specific sialylation patterns, which significantly strengthened our biomarker program. Cancer Immunology Lead, Dr. Han***

Functional Validation
The antibodies delivered blocked Siglec interactions effectively and showed strong ADCC activity in our tumor models, accelerating our preclinical testing. Translational Scientist, Dr. Vel***

Versatile Applications
With Creative Biolabs’ support, we developed both therapeutic and imaging-grade antibodies against sialylated epitopes, saving time and expanding the scope of our project. Research Director, Dr. Mor***

FAQs

Which sialic acid targets can be addressed?

We support antibodies against common tumor-associated motifs such as sialyl-Tn, sialyl-Lewis antigens, and customized client-defined epitopes.

How is specificity ensured for sialylated epitopes?

We employ glycan arrays, cell-based profiling, and structural validation to confirm selectivity and minimize off-target binding.

What applications are supported?

Our antibodies are suitable for biomarker validation, imaging, and basic research applications.

Extended Services

Sialic Acid Microarray Service

We provide high-throughput microarray platforms displaying diverse sialylated glycans to map antibody or lectin binding profiles with precision. This service enables rapid identification of tumor-associated sialic acid epitopes and supports antibody specificity validation.

Quantitative Sialic Acid Analysis Service

Our service offers accurate measurement of sialic acid levels using advanced chromatographic and mass spectrometric methods. It delivers a detailed quantification of total and linkage-specific sialic acids, essential for biomarker studies and therapeutic development.

Creative Biolabs delivers actionable solutions: highly specific antibodies designed to disrupt tumor sialylation pathways, optimized formats for therapeutic or diagnostic use, and functional data packages to guide development. Contact our team for more information and to discuss your project.

Reference

  1. Loureiro, Liliana R et al. “Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2-6 sialic acids.” Scientific Reports vol. 8,1 12196. 15 Aug. 2018. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41598-018-30421-w
For Research Use Only.

Related Services

Online Inquiry
Creative Biolabs-Glycoprotein Contact Us Follow us on
  • ()
    ()
    ()
ISO 9001 Certified - Creative Biolabs Quality Management System.
Close
Thanksgiving
Thanksgiving